Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations.

Nature communications - 10 Nov 2022

van Alderwerelt van Rosenburgh Iris K, Lu David M, Grant Michael J, Stayrook Steven E, Phadke Manali, Walther Zenta, Goldberg Sarah B, Politi Katerina, Lemmon Mark A, Ashtekar Kumar D, Tsutsui Yuko

Abstract excerpt

Tyrosine kinase inhibitors (TKIs) are used to treat non-small cell lung cancers (NSCLC) driven by epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain (TKD). TKI responses vary across tumors driven by the heterogeneous group of exon 19 deletions and mutations, but the molecular basis for these differences is not understood. Using purified TKDs, we compared kinetic properties of several...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HER2/EGFR in Cancer Research

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 36357385
DOI: 10.1038/s41467-022-34398-z
PMCID: PMC9649653

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations.PMID 36357385Read ↗

The EGFR Exon 19 Mutant L747-A750&gt;P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung AdenocarcinomaSemantic proximity Read ↗

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancerSemantic proximity Read ↗

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer.Semantic proximity Read ↗

Overcoming Resistance in EGFR-Mutant Cancers: A Comprehensive Review of Inhibitor Evolution and SAR-Based Design.Semantic proximity Read ↗

Structure-based classification for differential tyrosine kinase inhibitors efficacy of EGFR exon 19 deletions in non-small cell lung cancer.Semantic proximity Read ↗

Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors.Semantic proximity Read ↗

Coupled Solvent and Protein Dynamics Confer Differences in Exon-19 Deletion Mutants of the Epidermal Growth Factor Receptor KinaseSemantic proximity Read ↗

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.Semantic proximity Read ↗

Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor.Semantic proximity Read ↗

EGFR and tyrosine kinase inhibitor interactions probed by hydrogen-deuterium exchange and mass spectrometry (HDX-MS)Semantic proximity Read ↗

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.Semantic proximity Read ↗

Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.